vs
ANGIODYNAMICS INC（ANGO）与Apyx Medical Corp（APYX）财务数据对比。点击上方公司名可切换其他公司
ANGIODYNAMICS INC的季度营收约是Apyx Medical Corp的4.1倍（$79.4M vs $19.2M）。Apyx Medical Corp净利率更高（-6.8% vs -8.0%，领先1.2%）。Apyx Medical Corp同比增速更快（34.7% vs 9.0%）。ANGIODYNAMICS INC自由现金流更多（$4.2M vs $-2.8M）。过去两年Apyx Medical Corp的营收复合增速更高（36.8% vs 2.8%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
Apyx Medical前身是博维医疗，是美国的医疗器械制造商，专注生产电外科产品与能源技术相关医疗设备，公司总部位于佛罗里达州克利尔沃特，在保加利亚设有生产工厂。
ANGO vs APYX — 直观对比
营收规模更大
ANGO
是对方的4.1倍
$19.2M
营收增速更快
APYX
高出25.7%
9.0%
净利率更高
APYX
高出1.2%
-8.0%
自由现金流更多
ANGO
多$7.0M
$-2.8M
两年增速更快
APYX
近两年复合增速
2.8%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $19.2M |
| 净利润 | $-6.3M | $-1.3M |
| 毛利率 | 56.4% | 62.6% |
| 营业利润率 | -7.7% | 0.1% |
| 净利率 | -8.0% | -6.8% |
| 营收同比 | 9.0% | 34.7% |
| 净利润同比 | 40.9% | 71.9% |
| 每股收益（稀释后） | $-0.15 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGOAPYX
| Q4 25 | $79.4M | $19.2M | ||
| Q3 25 | $75.7M | $12.9M | ||
| Q2 25 | $80.2M | $11.4M | ||
| Q1 25 | $72.0M | $9.4M | ||
| Q4 24 | $72.8M | $14.2M | ||
| Q3 24 | $67.5M | $11.5M | ||
| Q2 24 | $71.0M | $12.1M | ||
| Q1 24 | $75.2M | $10.2M |
净利润ANGOAPYX
| Q4 25 | $-6.3M | $-1.3M | ||
| Q3 25 | $-10.9M | $-2.0M | ||
| Q2 25 | $-6.0M | $-3.8M | ||
| Q1 25 | $-4.4M | $-4.2M | ||
| Q4 24 | $-10.7M | $-4.6M | ||
| Q3 24 | $-12.8M | $-4.7M | ||
| Q2 24 | $-13.4M | $-6.6M | ||
| Q1 24 | $-187.7M | $-7.6M |
毛利率ANGOAPYX
| Q4 25 | 56.4% | 62.6% | ||
| Q3 25 | 55.3% | 64.4% | ||
| Q2 25 | 52.7% | 62.3% | ||
| Q1 25 | 54.0% | 60.1% | ||
| Q4 24 | 54.8% | 63.0% | ||
| Q3 24 | 54.4% | 60.5% | ||
| Q2 24 | 54.3% | 61.7% | ||
| Q1 24 | 47.7% | 58.1% |
营业利润率ANGOAPYX
| Q4 25 | -7.7% | 0.1% | ||
| Q3 25 | -14.1% | -6.5% | ||
| Q2 25 | -7.2% | -22.6% | ||
| Q1 25 | -13.9% | -32.4% | ||
| Q4 24 | -15.2% | -21.4% | ||
| Q3 24 | -19.4% | -31.6% | ||
| Q2 24 | -20.4% | -45.7% | ||
| Q1 24 | -265.9% | -64.6% |
净利率ANGOAPYX
| Q4 25 | -8.0% | -6.8% | ||
| Q3 25 | -14.4% | -15.4% | ||
| Q2 25 | -7.5% | -33.2% | ||
| Q1 25 | -6.1% | -44.0% | ||
| Q4 24 | -14.7% | -32.5% | ||
| Q3 24 | -19.0% | -40.9% | ||
| Q2 24 | -18.9% | -54.0% | ||
| Q1 24 | -249.7% | -74.0% |
每股收益（稀释后）ANGOAPYX
| Q4 25 | $-0.15 | — | ||
| Q3 25 | $-0.26 | — | ||
| Q2 25 | $-0.15 | — | ||
| Q1 25 | $-0.11 | — | ||
| Q4 24 | $-0.26 | — | ||
| Q3 24 | $-0.31 | — | ||
| Q2 24 | $-0.35 | $-0.19 | ||
| Q1 24 | $-4.67 | $-0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $31.7M |
| 总债务越低越好 | — | $37.5M |
| 股东权益账面价值 | $176.3M | $14.5M |
| 总资产 | $269.7M | $66.8M |
| 负债/权益比越低杠杆越低 | — | 2.58× |
8季度趋势，按日历期对齐
现金及短期投资ANGOAPYX
| Q4 25 | $41.6M | $31.7M | ||
| Q3 25 | $38.8M | $25.1M | ||
| Q2 25 | $55.9M | $29.3M | ||
| Q1 25 | $44.8M | $31.0M | ||
| Q4 24 | $54.1M | $31.7M | ||
| Q3 24 | $55.0M | $28.0M | ||
| Q2 24 | $76.1M | $32.7M | ||
| Q1 24 | $78.5M | $37.3M |
总债务ANGOAPYX
| Q4 25 | — | $37.5M | ||
| Q3 25 | — | $37.5M | ||
| Q2 25 | — | $37.5M | ||
| Q1 25 | — | $37.5M | ||
| Q4 24 | — | $37.5M | ||
| Q3 24 | — | $37.5M | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益ANGOAPYX
| Q4 25 | $176.3M | $14.5M | ||
| Q3 25 | $178.9M | $5.8M | ||
| Q2 25 | $183.0M | $7.3M | ||
| Q1 25 | $185.9M | $10.5M | ||
| Q4 24 | $186.8M | $14.2M | ||
| Q3 24 | $196.6M | $11.0M | ||
| Q2 24 | $205.6M | $14.7M | ||
| Q1 24 | $218.7M | $20.3M |
总资产ANGOAPYX
| Q4 25 | $269.7M | $66.8M | ||
| Q3 25 | $265.6M | $57.4M | ||
| Q2 25 | $280.1M | $58.2M | ||
| Q1 25 | $285.4M | $60.2M | ||
| Q4 24 | $291.6M | $64.8M | ||
| Q3 24 | $293.6M | $60.7M | ||
| Q2 24 | $317.7M | $65.4M | ||
| Q1 24 | $324.8M | $70.7M |
负债/权益比ANGOAPYX
| Q4 25 | — | 2.58× | ||
| Q3 25 | — | 6.41× | ||
| Q2 25 | — | 5.17× | ||
| Q1 25 | — | 3.57× | ||
| Q4 24 | — | 2.64× | ||
| Q3 24 | — | 3.40× | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | $-2.5M |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $-2.8M |
| 自由现金流率自由现金流/营收 | 5.3% | -14.6% |
| 资本支出强度资本支出/营收 | 0.5% | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $-9.1M |
8季度趋势，按日历期对齐
经营现金流ANGOAPYX
| Q4 25 | $4.7M | $-2.5M | ||
| Q3 25 | $-15.9M | $-3.5M | ||
| Q2 25 | $18.8M | $-1.2M | ||
| Q1 25 | $-13.2M | $-702.0K | ||
| Q4 24 | $2.5M | $-2.9M | ||
| Q3 24 | $-18.3M | $-4.4M | ||
| Q2 24 | $5.0M | $-4.3M | ||
| Q1 24 | $-12.5M | $-6.3M |
自由现金流ANGOAPYX
| Q4 25 | $4.2M | $-2.8M | ||
| Q3 25 | $-16.6M | $-4.1M | ||
| Q2 25 | $18.0M | $-1.5M | ||
| Q1 25 | $-15.0M | $-757.0K | ||
| Q4 24 | $1.7M | $-3.2M | ||
| Q3 24 | $-19.3M | $-4.6M | ||
| Q2 24 | $4.4M | $-4.6M | ||
| Q1 24 | $-13.1M | $-6.4M |
自由现金流率ANGOAPYX
| Q4 25 | 5.3% | -14.6% | ||
| Q3 25 | -22.0% | -31.5% | ||
| Q2 25 | 22.5% | -13.2% | ||
| Q1 25 | -20.8% | -8.0% | ||
| Q4 24 | 2.3% | -22.4% | ||
| Q3 24 | -28.7% | -40.0% | ||
| Q2 24 | 6.2% | -38.0% | ||
| Q1 24 | -17.5% | -62.2% |
资本支出强度ANGOAPYX
| Q4 25 | 0.5% | 1.4% | ||
| Q3 25 | 1.0% | 4.0% | ||
| Q2 25 | 1.0% | 2.3% | ||
| Q1 25 | 2.5% | 0.6% | ||
| Q4 24 | 1.1% | 1.7% | ||
| Q3 24 | 1.6% | 1.3% | ||
| Q2 24 | 0.8% | 2.4% | ||
| Q1 24 | 0.8% | 0.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
APYX
暂无分部数据
